Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Designing Second Generation Anti-Alzheimer Compounds as Inhibitors of Human Acetylcholinesterase: Computational Screening of Synthetic Molecules and Dietary Phytochemicals</title><author><name sortKey="Amat Ur Rasool, Hafsa" sort="Amat Ur Rasool, Hafsa" uniqKey="Amat Ur Rasool H" first="Hafsa" last="Amat-Ur-Rasool">Hafsa Amat-Ur-Rasool</name><affiliation><nlm:aff id="aff001"><addr-line>Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>National Center of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ahmed, Mehboob" sort="Ahmed, Mehboob" uniqKey="Ahmed M" first="Mehboob" last="Ahmed">Mehboob Ahmed</name><affiliation><nlm:aff id="aff001"><addr-line>Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan</addr-line></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26325402</idno><idno type="pmc">4556483</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4556483</idno><idno type="RBID">PMC:4556483</idno><idno type="doi">10.1371/journal.pone.0136509</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">000186</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Designing Second Generation Anti-Alzheimer Compounds as Inhibitors of Human Acetylcholinesterase: Computational Screening of Synthetic Molecules and Dietary Phytochemicals</title><author><name sortKey="Amat Ur Rasool, Hafsa" sort="Amat Ur Rasool, Hafsa" uniqKey="Amat Ur Rasool H" first="Hafsa" last="Amat-Ur-Rasool">Hafsa Amat-Ur-Rasool</name><affiliation><nlm:aff id="aff001"><addr-line>Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan</addr-line></nlm:aff></affiliation><affiliation><nlm:aff id="aff002"><addr-line>National Center of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan</addr-line></nlm:aff></affiliation></author><author><name sortKey="Ahmed, Mehboob" sort="Ahmed, Mehboob" uniqKey="Ahmed M" first="Mehboob" last="Ahmed">Mehboob Ahmed</name><affiliation><nlm:aff id="aff001"><addr-line>Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan</addr-line></nlm:aff></affiliation></author></analytic><series><title level="j">PLoS ONE</title><idno type="eISSN">1932-6203</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Alzheimer's disease (AD), a big cause of memory loss, is a progressive neurodegenerative disorder. The disease leads to irreversible loss of neurons that result in reduced level of acetylcholine neurotransmitter (ACh). The reduction of ACh level impairs brain functioning. One aspect of AD therapy is to maintain ACh level up to a safe limit, by blocking acetylcholinesterase (AChE), an enzyme that is naturally responsible for its degradation. This research presents an <italic>in-silico</italic> screening and designing of hAChE inhibitors as potential anti-Alzheimer drugs. Molecular docking results of the database retrieved (synthetic chemicals and dietary phytochemicals) and self-drawn ligands were compared with Food and Drug Administration (FDA) approved drugs against AD as controls. Furthermore, computational ADME studies were performed on the hits to assess their safety. Human AChE was found to be most approptiate target site as compared to commonly used Torpedo AChE. Among the tested dietry phytochemicals, berberastine, berberine, yohimbine, sanguinarine, elemol and naringenin are the worth mentioning phytochemicals as potential anti-Alzheimer drugs The synthetic leads were mostly dual binding site inhibitors with two binding subunits linked by a carbon chain i.e. second generation AD drugs. Fifteen new heterodimers were designed that were computationally more efficient inhibitors than previously reported compounds. Using computational methods, compounds present in online chemical databases can be screened to design more efficient and safer drugs against cognitive symptoms of AD.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Cummings, Jl" uniqKey="Cummings J">JL Cummings</name></author><author><name sortKey="Cole, G" uniqKey="Cole G">G Cole</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Davies, P" uniqKey="Davies P">P Davies</name></author><author><name sortKey="Maloney, Aj" uniqKey="Maloney A">AJ Maloney</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, J" uniqKey="Kim J">J Kim</name></author><author><name sortKey="Lee, Hj" uniqKey="Lee H">HJ Lee</name></author><author><name sortKey="Lee, Kw" uniqKey="Lee K">KW Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Iversen, L" uniqKey="Iversen L">L Iversen</name></author><author><name sortKey="Cottrell, G" uniqKey="Cottrell G">G Cottrell</name></author><author><name sortKey="Usherwood, P" uniqKey="Usherwood P">P Usherwood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bartus, Rt" uniqKey="Bartus R">RT Bartus</name></author><author><name sortKey="Dean, Rl" uniqKey="Dean R">RL Dean</name></author><author><name sortKey="Beer, B" uniqKey="Beer B">B Beer</name></author><author><name sortKey="Lippa, As" uniqKey="Lippa A">AS Lippa</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Holland, D" uniqKey="Holland D">D Holland</name></author><author><name sortKey="Desikan, Rs" uniqKey="Desikan R">RS Desikan</name></author><author><name sortKey="Dale, Am" uniqKey="Dale A">AM Dale</name></author><author><name sortKey="Mcevoy, Lk" uniqKey="Mcevoy L">LK McEvoy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Massoulie, J" uniqKey="Massoulie J">J Massoulié</name></author><author><name sortKey="Pezzementi, L" uniqKey="Pezzementi L">L Pezzementi</name></author><author><name sortKey="Bon, S" uniqKey="Bon S">S Bon</name></author><author><name sortKey="Krejci, E" uniqKey="Krejci E">E Krejci</name></author><author><name sortKey="Vallette, F M" uniqKey="Vallette F">F-M Vallette</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Heinrich, M" uniqKey="Heinrich M">M Heinrich</name></author><author><name sortKey="Lee Teoh, H" uniqKey="Lee Teoh H">H Lee Teoh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grutzendler, J" uniqKey="Grutzendler J">J Grutzendler</name></author><author><name sortKey="Morris, Jc" uniqKey="Morris J">JC Morris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Winblad, B" uniqKey="Winblad B">B Winblad</name></author><author><name sortKey="Jelic, V" uniqKey="Jelic V">V Jelic</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kryger, G" uniqKey="Kryger G">G Kryger</name></author><author><name sortKey="Silman, I" uniqKey="Silman I">I Silman</name></author><author><name sortKey="Sussman, Jl" uniqKey="Sussman J">JL Sussman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bartolucci, C" uniqKey="Bartolucci C">C Bartolucci</name></author><author><name sortKey="Perola, E" uniqKey="Perola E">E Perola</name></author><author><name sortKey="Pilger, C" uniqKey="Pilger C">C Pilger</name></author><author><name sortKey="Fels, G" uniqKey="Fels G">G Fels</name></author><author><name sortKey="Lamba, D" uniqKey="Lamba D">D Lamba</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Greenblatt, H" uniqKey="Greenblatt H">H Greenblatt</name></author><author><name sortKey="Kryger, G" uniqKey="Kryger G">G Kryger</name></author><author><name sortKey="Lewis, T" uniqKey="Lewis T">T Lewis</name></author><author><name sortKey="Silman, I" uniqKey="Silman I">I Silman</name></author><author><name sortKey="Sussman, J" uniqKey="Sussman J">J Sussman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jann, Mw" uniqKey="Jann M">MW Jann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schulz, V" uniqKey="Schulz V">V Schulz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mukherjee, Pk" uniqKey="Mukherjee P">PK Mukherjee</name></author><author><name sortKey="Kumar, V" uniqKey="Kumar V">V Kumar</name></author><author><name sortKey="Houghton, Pj" uniqKey="Houghton P">PJ Houghton</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lipinski, Ca" uniqKey="Lipinski C">CA Lipinski</name></author><author><name sortKey="Lombardo, F" uniqKey="Lombardo F">F Lombardo</name></author><author><name sortKey="Dominy, Bw" uniqKey="Dominy B">BW Dominy</name></author><author><name sortKey="Feeney, Pj" uniqKey="Feeney P">PJ Feeney</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kaduszkiewicz, H" uniqKey="Kaduszkiewicz H">H Kaduszkiewicz</name></author><author><name sortKey="Zimmermann, T" uniqKey="Zimmermann T">T Zimmermann</name></author><author><name sortKey="Beck Bornholdt, H P" uniqKey="Beck Bornholdt H">H-P Beck-Bornholdt</name></author><author><name sortKey="Van Den Bussche, H" uniqKey="Van Den Bussche H">H van den Bussche</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sussman, Jl" uniqKey="Sussman J">JL Sussman</name></author><author><name sortKey="Harel, M" uniqKey="Harel M">M Harel</name></author><author><name sortKey="Frolow, F" uniqKey="Frolow F">F Frolow</name></author><author><name sortKey="Oefner, C" uniqKey="Oefner C">C Oefner</name></author><author><name sortKey="Goldman, A" uniqKey="Goldman A">A Goldman</name></author><author><name sortKey="Toker, L" uniqKey="Toker L">L Toker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sussman, Jl" uniqKey="Sussman J">JL Sussman</name></author><author><name sortKey="Harel, M" uniqKey="Harel M">M Harel</name></author><author><name sortKey="Frolow, F" uniqKey="Frolow F">F Frolow</name></author><author><name sortKey="Oefner, C" uniqKey="Oefner C">C Oefner</name></author><author><name sortKey="Goldman, A" uniqKey="Goldman A">A Goldman</name></author><author><name sortKey="Toker, L" uniqKey="Toker L">L Toker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dvir, H" uniqKey="Dvir H">H Dvir</name></author><author><name sortKey="Jiang, Hl" uniqKey="Jiang H">HL Jiang</name></author><author><name sortKey="Wong, Dm" uniqKey="Wong D">DM Wong</name></author><author><name sortKey="Harel, M" uniqKey="Harel M">M Harel</name></author><author><name sortKey="Chetrit, M" uniqKey="Chetrit M">M Chetrit</name></author><author><name sortKey="He, Xc" uniqKey="He X">XC He</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheung, J" uniqKey="Cheung J">J Cheung</name></author><author><name sortKey="Rudolph, Mj" uniqKey="Rudolph M">MJ Rudolph</name></author><author><name sortKey="Burshteyn, F" uniqKey="Burshteyn F">F Burshteyn</name></author><author><name sortKey="Cassidy, Ms" uniqKey="Cassidy M">MS Cassidy</name></author><author><name sortKey="Gary, En" uniqKey="Gary E">EN Gary</name></author><author><name sortKey="Love, J" uniqKey="Love J">J Love</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Potestio, R" uniqKey="Potestio R">R Potestio</name></author><author><name sortKey="Aleksiev, T" uniqKey="Aleksiev T">T Aleksiev</name></author><author><name sortKey="Pontiggia, F" uniqKey="Pontiggia F">F Pontiggia</name></author><author><name sortKey="Cozzini, S" uniqKey="Cozzini S">S Cozzini</name></author><author><name sortKey="Micheletti, C" uniqKey="Micheletti C">C Micheletti</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kelley, La" uniqKey="Kelley L">LA Kelley</name></author><author><name sortKey="Sternberg, Mj" uniqKey="Sternberg M">MJ Sternberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Amat Ur Rasool, H" uniqKey="Amat Ur Rasool H">H Amat-ur-Rasool</name></author><author><name sortKey="Saghir, A" uniqKey="Saghir A">A Saghir</name></author><author><name sortKey="Idrees, M" uniqKey="Idrees M">M Idrees</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ye, Y" uniqKey="Ye Y">Y Ye</name></author><author><name sortKey="Godzik, A" uniqKey="Godzik A">A Godzik</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Schneidman Duhovny, D" uniqKey="Schneidman Duhovny D">D Schneidman-Duhovny</name></author><author><name sortKey="Inbar, Y" uniqKey="Inbar Y">Y Inbar</name></author><author><name sortKey="Nussinov, R" uniqKey="Nussinov R">R Nussinov</name></author><author><name sortKey="Wolfson, Hj" uniqKey="Wolfson H">HJ Wolfson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mendelsohn, Ld" uniqKey="Mendelsohn L">LD Mendelsohn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ashani, Y" uniqKey="Ashani Y">Y Ashani</name></author><author><name sortKey="Peggins, Jo" uniqKey="Peggins J">JO Peggins</name></author><author><name sortKey="Doctor, Bp" uniqKey="Doctor B">BP Doctor</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lanctot, Kl" uniqKey="Lanctot K">KL Lanctot</name></author><author><name sortKey="Rajaram, Rd" uniqKey="Rajaram R">RD Rajaram</name></author><author><name sortKey="Herrmann, N" uniqKey="Herrmann N">N Herrmann</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Monte, Mm" uniqKey="Monte M">MM Monte</name></author><author><name sortKey="Garcia Palomero, E" uniqKey="Garcia Palomero E">E García Palomero</name></author><author><name sortKey="Valenzuela, R" uniqKey="Valenzuela R">R Valenzuela</name></author><author><name sortKey="Usan, P" uniqKey="Usan P">P Usán</name></author><author><name sortKey="De Austria, C" uniqKey="De Austria C">C de Austria</name></author><author><name sortKey="Mu Oz Ruiz, P" uniqKey="Mu Oz Ruiz P">P Muñoz Ruiz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Giacobini, E" uniqKey="Giacobini E">E Giacobini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Boado, Rj" uniqKey="Boado R">RJ Boado</name></author><author><name sortKey="Tsukamoto, H" uniqKey="Tsukamoto H">H Tsukamoto</name></author><author><name sortKey="Pardridge, Wm" uniqKey="Pardridge W">WM Pardridge</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoffmann, D" uniqKey="Hoffmann D">D Hoffmann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Abascal, K" uniqKey="Abascal K">K Abascal</name></author><author><name sortKey="Yarnell, E" uniqKey="Yarnell E">E Yarnell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Imanshahidi, M" uniqKey="Imanshahidi M">M Imanshahidi</name></author><author><name sortKey="Hosseinzadeh, H" uniqKey="Hosseinzadeh H">H Hosseinzadeh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ji, H F" uniqKey="Ji H">H-F Ji</name></author><author><name sortKey="Shen, L" uniqKey="Shen L">L Shen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Farnsworth, Nr" uniqKey="Farnsworth N">NR Farnsworth</name></author><author><name sortKey="Blomster, Rn" uniqKey="Blomster R">RN Blomster</name></author><author><name sortKey="Buckley, J" uniqKey="Buckley J">J Buckley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mroue, Ma" uniqKey="Mroue M">MA Mroue</name></author><author><name sortKey="Euler, Kl" uniqKey="Euler K">KL Euler</name></author><author><name sortKey="Ghuman, Ma" uniqKey="Ghuman M">MA Ghuman</name></author><author><name sortKey="Alam, M" uniqKey="Alam M">M Alam</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kutchan, Tm" uniqKey="Kutchan T">TM Kutchan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Houghton, Pj" uniqKey="Houghton P">PJ Houghton</name></author><author><name sortKey="Ren, Y" uniqKey="Ren Y">Y Ren</name></author><author><name sortKey="Howes, M J" uniqKey="Howes M">M-J Howes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Heo, Hj" uniqKey="Heo H">HJ Heo</name></author><author><name sortKey="Kim, M J" uniqKey="Kim M">M-J Kim</name></author><author><name sortKey="Lee, J M" uniqKey="Lee J">J-M Lee</name></author><author><name sortKey="Choi, Sj" uniqKey="Choi S">SJ Choi</name></author><author><name sortKey="Cho, H Y" uniqKey="Cho H">H-Y Cho</name></author><author><name sortKey="Hong, B" uniqKey="Hong B">B Hong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cavalli, A" uniqKey="Cavalli A">A Cavalli</name></author><author><name sortKey="Bolognesi, Ml" uniqKey="Bolognesi M">ML Bolognesi</name></author><author><name sortKey="Minarini, A" uniqKey="Minarini A">A Minarini</name></author><author><name sortKey="Rosini, M" uniqKey="Rosini M">M Rosini</name></author><author><name sortKey="Tumiatti, V" uniqKey="Tumiatti V">V Tumiatti</name></author><author><name sortKey="Recanatini, M" uniqKey="Recanatini M">M Recanatini</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26325402</article-id><article-id pub-id-type="pmc">4556483</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0136509</article-id><article-id pub-id-type="publisher-id">PONE-D-15-15741</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Designing Second Generation Anti-Alzheimer Compounds as Inhibitors of Human Acetylcholinesterase: Computational Screening of Synthetic Molecules and Dietary Phytochemicals</article-title><alt-title alt-title-type="running-head">2nd Gen. Anti-Alzheimer Compounds</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Amat-ur-Rasool</surname><given-names>Hafsa</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ahmed</surname><given-names>Mehboob</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Microbiology and Molecular Genetics, University of the Punjab, Lahore, Pakistan</addr-line></aff><aff id="aff002"><label>2</label><addr-line>National Center of Excellence in Molecular Biology, University of the Punjab, Lahore, Pakistan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Akaaboune</surname><given-names>Mohammed</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"></xref></contrib></contrib-group><aff id="edit1"><addr-line>University of Michigan, UNITED STATES</addr-line></aff><author-notes><fn fn-type="conflict" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: HAR MA. Performed the experiments: HAR. Analyzed the data: HAR MA. Contributed reagents/materials/analysis tools: HAR MA. Wrote the paper: HAR MA.</p></fn><corresp id="cor001">* E-mail: <email>mehboob.mmg@pu.edu.pk</email></corresp></author-notes><pub-date pub-type="epub"><day>1</day><month>9</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>9</issue><elocation-id>e0136509</elocation-id><history><date date-type="received"><day>11</day><month>4</month><year>2015</year></date><date date-type="accepted"><day>5</day><month>8</month><year>2015</year></date></history><permissions><copyright-year>2015</copyright-year><copyright-holder>Amat-ur-Rasool, Ahmed</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0136509.pdf"></self-uri><abstract><p>Alzheimer's disease (AD), a big cause of memory loss, is a progressive neurodegenerative disorder. The disease leads to irreversible loss of neurons that result in reduced level of acetylcholine neurotransmitter (ACh). The reduction of ACh level impairs brain functioning. One aspect of AD therapy is to maintain ACh level up to a safe limit, by blocking acetylcholinesterase (AChE), an enzyme that is naturally responsible for its degradation. This research presents an <italic>in-silico</italic> screening and designing of hAChE inhibitors as potential anti-Alzheimer drugs. Molecular docking results of the database retrieved (synthetic chemicals and dietary phytochemicals) and self-drawn ligands were compared with Food and Drug Administration (FDA) approved drugs against AD as controls. Furthermore, computational ADME studies were performed on the hits to assess their safety. Human AChE was found to be most approptiate target site as compared to commonly used Torpedo AChE. Among the tested dietry phytochemicals, berberastine, berberine, yohimbine, sanguinarine, elemol and naringenin are the worth mentioning phytochemicals as potential anti-Alzheimer drugs The synthetic leads were mostly dual binding site inhibitors with two binding subunits linked by a carbon chain i.e. second generation AD drugs. Fifteen new heterodimers were designed that were computationally more efficient inhibitors than previously reported compounds. Using computational methods, compounds present in online chemical databases can be screened to design more efficient and safer drugs against cognitive symptoms of AD.</p></abstract><funding-group><funding-statement>The authors have no support or funding to report.</funding-statement></funding-group><counts><fig-count count="4"></fig-count><table-count count="2"></table-count><page-count count="11"></page-count></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Alzheimer's disease (AD), the most common cause of dementia in older people, is a progressive neurodegenerative disorder [<xref rid="pone.0136509.ref001" ref-type="bibr">1</xref>]. In year 2013, globally 44 million people suffered from this disease and the figure is predicted to rise up to 135 million sufferers by 2050 [<xref rid="pone.0136509.ref002" ref-type="bibr">2</xref>]. The disease is associated with appearance of plaques and tangles in brain tissue that gradually kills neurons in brain cortex, hippocampus, amygdala and certain other brain regions [<xref rid="pone.0136509.ref003" ref-type="bibr">3</xref>]. Due to non-regenerateable nature of neurons, the levels of acetylcholine (ACh) neurotransmitter produced by them declines [<xref rid="pone.0136509.ref001" ref-type="bibr">1</xref>]. This is known as cholinergic-deficit hypothesis for the AD [<xref rid="pone.0136509.ref004" ref-type="bibr">4</xref>]. Normally ACh is broken down instantly, as soon as it is produced, due to the activity of enzyme known as acetylcholinesterase (AChE) present in neural synapse [<xref rid="pone.0136509.ref005" ref-type="bibr">5</xref>]. Sufficient ACh is required for proper brain functioning, but due to decreased ACh in AD patients, they suffer from progressive decline in cognitive functioning (thinking, remembering, and reasoning) and behavioral abilities [<xref rid="pone.0136509.ref006" ref-type="bibr">6</xref>]. The symptoms start usually at age of 65 years with short term memory loss, lately long term memory loss and eventually lead to death due to multiple organ failure within approximately 8 years of onset [<xref rid="pone.0136509.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0136509.ref008" ref-type="bibr">8</xref>]. There is no effective treatment available till date, but inhibition of ACh breakdown by blocking the AChE, has been proved to be helpful in slowing down the disease progression [<xref rid="pone.0136509.ref009" ref-type="bibr">9</xref>].</p><p>Nearly all FDA approved drugs for AD therapy are acetylcholinesterase inhibitors [<xref rid="pone.0136509.ref010" ref-type="bibr">10</xref>] and their effectiveness is credited to the degree of inhibition of the enzyme [<xref rid="pone.0136509.ref011" ref-type="bibr">11</xref>]. Tacrine approved by FDA in 1993 was the first AChE inhibitor used for the treatment of AD [<xref rid="pone.0136509.ref012" ref-type="bibr">12</xref>]. Currently only few other AChE inhibitors such as donepezil [<xref rid="pone.0136509.ref013" ref-type="bibr">13</xref>], galantamine [<xref rid="pone.0136509.ref014" ref-type="bibr">14</xref>], huperzine-A [<xref rid="pone.0136509.ref015" ref-type="bibr">15</xref>] and rivastigmine [<xref rid="pone.0136509.ref016" ref-type="bibr">16</xref>] are generally used for treating cognitive symptoms in persons with mild or moderate AD [<xref rid="pone.0136509.ref011" ref-type="bibr">11</xref>]. But there are certain adverse effects associated with these inhibitors like dizziness, headache, constipation, hepatotoxicity, nausea, diarrhea, and bioavailability complications [<xref rid="pone.0136509.ref017" ref-type="bibr">17</xref>]. This stimulated the researchers to discover AChE inhibitors that are more effective and preferably produced by natural resources in order to minimize the side effects of the drugs [<xref rid="pone.0136509.ref018" ref-type="bibr">18</xref>]. Various experimental and computational approaches are in use for bioavailability studies, as a result compounds with poorer physical and chemical properties are filtered out at earlier stages before they enter clinical trials [<xref rid="pone.0136509.ref019" ref-type="bibr">19</xref>]. Until now about 400 inhibitors of AChE have been reported as alternate treatment options for AD [<xref rid="pone.0136509.ref020" ref-type="bibr">20</xref>].</p><p>Acetylcholinesterase is naturally abundant in electricity generating organs of torpedo ray and the X-ray crystal structures for torpedo AChE (tAChE) has been determined long before [<xref rid="pone.0136509.ref021" ref-type="bibr">21</xref>]. Since then, tAChE has been an extensively used source of the enzyme in AD therapy research [<xref rid="pone.0136509.ref022" ref-type="bibr">22</xref>]. Many reported synthetic and natural AD drug candidates as well as FDA approved drugs had been analyzed by using tAChE complexes instead of hAChE [<xref rid="pone.0136509.ref013" ref-type="bibr">13</xref>–<xref rid="pone.0136509.ref015" ref-type="bibr">15</xref>, <xref rid="pone.0136509.ref023" ref-type="bibr">23</xref>]. Later on, Cheung et al. [<xref rid="pone.0136509.ref024" ref-type="bibr">24</xref>] reported that donepezil binds to tAChE in a significantly altered conformation as compared to recombinant hAChE (PDB: 4EY7) indicating that hAChE is more specific for drug discovery research [<xref rid="pone.0136509.ref024" ref-type="bibr">24</xref>].</p><p>In the present work, a comparison of human and torpedo AChE enzymes was done at sequence and structural levels to check dissimilarities. Docking studies were performed by using modeled hAChE to get more specific results for the human enzyme. Derivatives and heterodimers of FDA approved drugs for AD as well as phytochemicals with anti-AChE activity, retrieved from online databases, were screened on the basis of docking score and ADME criteria. Moreover, on the basis of information obtained from lead structures, we designed more efficient heterodimer leads that can be further be tested experimentally to become second generation drug candidates for AD.</p></sec><sec id="sec002"><title>Tools and Methods</title><sec id="sec003"><title>hAChE Vs. tAChE</title><p>As no required reference amino acid sequences of hAChE Vs. tAChE were available in databases, representative amino acid sequences of hAChE (PDB: 2X8B chain A) and tAChE (PDB: 1EVE) were selected on the basis of multiple sequence alignment using Clustal Omega (<ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/Tools/msa/clustalo/">http://www.ebi.ac.uk/Tools/msa/clustalo/</ext-link>). These sequences were pairwise aligned by using EMBOSS-Needle (<ext-link ext-link-type="uri" xlink:href="http://www.ebi.ac.uk/Tools/psa/emboss_needle/">http://www.ebi.ac.uk/Tools/psa/emboss_needle/</ext-link>). Pairwise alignment of 3D protein structures was performed between PDB entry 2X8B chain A for human and PDB entry 1EVE for <italic>Torpedo californica</italic> AChE by using online tool ALADYN (<ext-link ext-link-type="uri" xlink:href="http://aladyn.escience-lab.org/">http://aladyn.escience-lab.org/</ext-link>) [<xref rid="pone.0136509.ref025" ref-type="bibr">25</xref>].</p></sec><sec id="sec004"><title>Homology Modeling of hAChE</title><p>The amino acid sequence GI: 295321523 (PDB: 2X8B_A) comprising of 583 amino acid residues was retrieved from NCBI-protein database and homology modeled by using Phyre2 V 2.0 server (<ext-link ext-link-type="uri" xlink:href="http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index">http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index</ext-link>) [<xref rid="pone.0136509.ref026" ref-type="bibr">26</xref>]. The server uses PSI-BLAST to find homologue templates to model the 3D structure of provided sequence accordingly [<xref rid="pone.0136509.ref027" ref-type="bibr">27</xref>]. The predicted structure was pairwise aligned with PDB entries 2X8B_A and 4EY4 by using FATCAT server (<ext-link ext-link-type="uri" xlink:href="http://fatcat.burnham.org/fatcat-cgi/cgi/fatcat.pl?-func=pairwise">http://fatcat.burnham.org/fatcat-cgi/cgi/fatcat.pl?-func=pairwise</ext-link>) [<xref rid="pone.0136509.ref028" ref-type="bibr">28</xref>].</p></sec><sec id="sec005"><title>Molecular Docking</title><p>FDA approved drugs for AD (controls), their derivatives and heterodimers, food, Generally Recognized As Safe (GRAS) and medicinal grade phytochemicals with anti-AChE activity according to Dr. Duke's phytochemical and ethnobotanical databases (<ext-link ext-link-type="uri" xlink:href="http://www.ars-grin.gov/duke/">http://www.ars-grin.gov/duke/</ext-link>) [<xref rid="pone.0136509.ref029" ref-type="bibr">29</xref>] were retrieved from three different databases (NCBI-PubChem Compound, ChemSpider and DrugBank). The modeled hAChE was docked with 329 hits. PatchDock server (<ext-link ext-link-type="uri" xlink:href="http://bioinfo3d.cs.tau.ac.il/PatchDock/">http://bioinfo3d.cs.tau.ac.il/PatchDock/</ext-link>)[<xref rid="pone.0136509.ref030" ref-type="bibr">30</xref>] was used as molecular-docking tool in order to determine enzyme (hAChE)-inhibitor binding affinities. The server was operated at Clustering RMSD value 4.0 and enzyme-inhibitor complex type. Results were evaluated by using top five poses for each hits on the basis of score, approximate interface area of the complex, atomic contact energy (ACE) and 3D transformation values. The output images were generated with PyMOL v 1.3 with hydrogen bonds lengths measured in Å.</p><p>The score values of FDA approved drugs were used as control, and were compared with that of hits by using following formula:
<disp-formula id="pone.0136509.e001"><alternatives><graphic xlink:href="pone.0136509.e001.jpg" id="pone.0136509.e001g" position="anchor" mimetype="image" orientation="portrait"></graphic><mml:math id="M1"><mml:mi mathvariant="normal">%</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="normal">d</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mo>–</mml:mo><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mo>)</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mo>×</mml:mo><mml:mi mathvariant="normal"> </mml:mi><mml:mn>100</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">S</mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal"> </mml:mi><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">l</mml:mi></mml:mrow></mml:mfrac></mml:math></alternatives></disp-formula></p></sec><sec id="sec006"><title><italic>In-silico</italic> ADME Prediction</title><p>Top scoring 40 hits and 10 phytochemical hits were subjected to computational ADME (absorption, distribution, metabolism, and excretion) studies by using online Lipinski filter supported by SCFBio (<ext-link ext-link-type="uri" xlink:href="http://www.scfbio-iitd.res.in/software/utility/LipinskiFilters.jsp">http://www.scfbio-iitd.res.in/software/utility/LipinskiFilters.jsp</ext-link>). The classical five properties for druglikeliness were analyzed i.e. molecular mass, octanol/water partition coefficient (CLogP), number of H-bond donors, number of H-bond acceptors and molecular refractivity.</p></sec><sec id="sec007"><title>Heterodimer Designing</title><p>Fifteen new heterodimers were designed on the basis of molecular structure analysis of leads. The lead phytochemicals berberastine and berberine were joined with tacrine and pyrimidine with a C-linker by using ChemDraw Ultra 8.0 [<xref rid="pone.0136509.ref031" ref-type="bibr">31</xref>]. Docking studies were performed and their druglikeliness was determined by methods described above.</p></sec></sec><sec id="sec008"><title>Results and Discussion</title><sec id="sec009"><title>Comparison of tAChE and hAChE</title><p>Pairwise alignment of human and <italic>Torpedo californica</italic> AChE sequences showed multiple mismatches and gaps between the two sequences. EMBOSS-Needle calculated 53.3% identity and 69.6% similarity between the two sequences using EBLOSUM62 matrix. The alignment generated is shown in <xref rid="pone.0136509.g001" ref-type="fig">Fig 1A</xref>. As the tertiary structures protein of remained more conserved in evolution than their amino acid sequences, alignment was performed between 3D structures of hAChE (2X8B_A: 536 a.a) and <italic>Tc</italic>AChE (1EVE: 534 a.a). A total of 517 amino acid residues were perfectly aligned between the two proteins and root mean square distance (RMSD) of the aligned regions was 1.8 Å. By using FATCAT algorithm [<xref rid="pone.0136509.ref028" ref-type="bibr">28</xref>] percentage similarity was calculated between the two structures that came out to be 75%. 3D alignment of the two structures is shown in <xref rid="pone.0136509.g001" ref-type="fig">Fig 1B</xref>. The difference between the human and torpedo enzyme at the levels of sequence and structure can probably have significant effect on ligand binding conformations.</p><fig id="pone.0136509.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0136509.g001</object-id><label>Fig 1</label><caption><title>Alignment of human and <italic>Torpedo californica</italic> AChE.</title><p>(A)Amino acid sequence alignment generated by RMBOSS-Needle. (B) 3D structure alignment of PDB entry 2X8B chain A for human and PDB entry 1EVE for <italic>Torpedo californica</italic> AChE generated by online tool Aladyn.</p></caption><graphic xlink:href="pone.0136509.g001"></graphic></fig></sec><sec id="sec010"><title>Homology Modeling of Human Acetylcholinesterase</title><p>The Phyre2 (Protein Homology/AnalogY Recognition Engine) is one of most popular methods for protein structure prediction [<xref rid="pone.0136509.ref026" ref-type="bibr">26</xref>]. The server found maximum similarity of the target sequence provided (GI: 295321523) with fold library id: d2ha2a1. It used X-ray crystal structure d2ha2a1 as template and modeled the target. A total of 536 residues out of 583 residues (92% of sequence) were modeled with 100% confidence. The software classified the enzyme as superfamily alpha/beta-hydrolases and family as acetylcholinesterase-like enzyme. The modeled hAChE structure alignment with PDB entries 2X8B_A and 4EY4 (the two crystal structures available for human enzyme in PDB) by using FATCAT algorithm, showed 99.3% and 99% similarity with RMSD 0.32 and 0.65 respectively. The high percentage similarity indicates that the modeled hAChE (99% similar) is a better target for molecular docking as compared to torpedo enzyme (75% similar). Images of modeled hAChE indicating the active site is shown in <xref rid="pone.0136509.g002" ref-type="fig">Fig 2A and 2B</xref>.</p><fig id="pone.0136509.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0136509.g002</object-id><label>Fig 2</label><caption><title>hAChE 3D structure modeled by Phyre2.</title><p>(A) Cartoon representation, key residues are represented in green sticks with the catalytic triad in red. (B) Surface representation, looking down catalytic groove. Images generated by using PyMOL v1.3.</p></caption><graphic xlink:href="pone.0136509.g002"></graphic></fig></sec><sec id="sec011"><title>Molecular Docking and Druglikeliness</title><p>Five commonly used FDA approved drugs for AD (Donepezil, Galantamine, Huperzine A, Rivastigmine and Tacrine) were selected and docked with the hAChE. These all turn down the breakdown of acetylcholine in the brain. This lead to increased levels of acetyl-choline in the brain, and may preserve brain function [<xref rid="pone.0136509.ref032" ref-type="bibr">32</xref>, <xref rid="pone.0136509.ref033" ref-type="bibr">33</xref>]. The docking score values came out to be in the order of: Donepezil (5998) > Rivastigmine (5998) > Galantamine (4676) > Huperzine A (4232) > Tacrine (4872). According to a Consumer Reports, when the efficiency of these treatments for AD were compared, majority of patients (upto 43%) left tacrine treatment due to its side effects, whereas this ratio was significantly lower for donepezil and galantamine treatment (19 and 17% respectively) [<xref rid="pone.0136509.ref034" ref-type="bibr">34</xref>]. So docking score can give us an information about the efficiency of possible drug. Out of synthetically designed database hits, CID: 21158810 came out to be the highest scoring synthetic compound fulfilling the criteria of ADME [<xref rid="pone.0136509.ref019" ref-type="bibr">19</xref>]. Present study showed that the hit CID: 21158810 is 81% more effective inhibitor as compared to tacrine and 19% more than that of donepezil (<xref rid="pone.0136509.t001" ref-type="table">Table 1</xref>). Moreover, the <xref rid="pone.0136509.t001" ref-type="table">Table 1</xref> indicates that majority of the synthetic leads are dual binding site inhibitors i.e. having two binding subunits with a chain of usually 8–12 C atoms between individual components. These inhibitors bind to active site as well as catalytic groove of acetylcholinesterase and belong to second generation AD drugs category [<xref rid="pone.0136509.ref035" ref-type="bibr">35</xref>]. As they bind the target at two sites they are more potent inhibitors [<xref rid="pone.0136509.ref036" ref-type="bibr">36</xref>]. Lipinski's rule of five is traditionally used to evaluate druglikeness or oral bioavailability of drugs in humans. It identifies five critical properties that are molecular mass <500 Da, octanol/water partition coefficient (LogP) <5, number of hydrogen-bond donors <5, number of hydrogen-bond acceptors <10 and molecular reactivity between 40 and 130 [<xref rid="pone.0136509.ref019" ref-type="bibr">19</xref>]. The rule describes molecular properties important for ADME (absorption, distribution, metabolism, and excretion), but, the rule does not predict pharmacological activity. It predicts high probability of clinical failure for molecules disobeying two or more of the rules [<xref rid="pone.0136509.ref019" ref-type="bibr">19</xref>]. The criteria for molecular weight <500Da was modified to <600Da to increase the hit rate, as the big active site of the enzyme require bigger drug molecules to cover it (<xref rid="pone.0136509.s001" ref-type="supplementary-material">S1 Table</xref>) [<xref rid="pone.0136509.ref037" ref-type="bibr">37</xref>].</p><table-wrap id="pone.0136509.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0136509.t001</object-id><label>Table 1</label><caption><title>Details of top leads fulfilling ADME criteria, and their score comparison to FDA approved drugs (Tacrine, Huperzine A, Galatamine, Rivastigmine, Donpezil) for AD.</title></caption><alternatives><graphic id="pone.0136509.t001g" xlink:href="pone.0136509.t001"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Lead type</th><th align="center" rowspan="1" colspan="1">Ligand</th><th align="center" rowspan="1" colspan="1">2D Structures</th><th align="center" rowspan="1" colspan="1">Score</th><th colspan="5" align="center" rowspan="1">%age Increase/Decrease in docking Score as Compared to FDA approved drugs for AD</th></tr><tr><th align="center" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1"></th><th align="center" rowspan="1" colspan="1">Tacrine</th><th align="center" rowspan="1" colspan="1">Huperzine A</th><th align="center" rowspan="1" colspan="1">Galatamine</th><th align="center" rowspan="1" colspan="1">Rivastigmine</th><th align="center" rowspan="1" colspan="1">Donpezil</th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">SL-1</td><td align="center" rowspan="1" colspan="1">CID_21158810</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0136509.g003" ref-type="fig">Fig 3A</xref></td><td align="center" rowspan="1" colspan="1">7120</td><td align="center" rowspan="1" colspan="1">81</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">19</td></tr><tr><td align="center" rowspan="1" colspan="1">SL-2</td><td align="center" rowspan="1" colspan="1">CID_5326967</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0136509.g003" ref-type="fig">Fig 3B</xref></td><td align="center" rowspan="1" colspan="1">6934</td><td align="center" rowspan="1" colspan="1">76</td><td align="center" rowspan="1" colspan="1">64</td><td align="center" rowspan="1" colspan="1">48</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">16</td></tr><tr><td align="center" rowspan="1" colspan="1">SL-3</td><td align="center" rowspan="1" colspan="1">CID_23645226</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0136509.g003" ref-type="fig">Fig 3C</xref></td><td align="center" rowspan="1" colspan="1">6872</td><td align="center" rowspan="1" colspan="1">74</td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">47</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">15</td></tr><tr><td align="center" rowspan="1" colspan="1">SL-4</td><td align="center" rowspan="1" colspan="1">CID_16094871</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0136509.g003" ref-type="fig">Fig 3D</xref></td><td align="center" rowspan="1" colspan="1">6726</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">12</td></tr><tr><td align="center" rowspan="1" colspan="1">SL-5</td><td align="center" rowspan="1" colspan="1">CID_5326966</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0136509.g003" ref-type="fig">Fig 3E</xref></td><td align="center" rowspan="1" colspan="1">6640</td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">36</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="center" rowspan="1" colspan="1">PL-1</td><td align="center" rowspan="1" colspan="1">Berberastine</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0136509.g003" ref-type="fig">Fig 3F</xref></td><td align="center" rowspan="1" colspan="1">5520</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">-8</td></tr><tr><td align="center" rowspan="1" colspan="1">PL-2</td><td align="center" rowspan="1" colspan="1">Berberine</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0136509.g003" ref-type="fig">Fig 3G</xref></td><td align="center" rowspan="1" colspan="1">5462</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">-9</td></tr><tr><td align="center" rowspan="1" colspan="1">PL-3</td><td align="center" rowspan="1" colspan="1">Yohimbine</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0136509.g003" ref-type="fig">Fig 3H</xref></td><td align="center" rowspan="1" colspan="1">5104</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">-15</td></tr><tr><td align="center" rowspan="1" colspan="1">PL-4</td><td align="center" rowspan="1" colspan="1">Sanguinarine</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0136509.g003" ref-type="fig">Fig 3I</xref></td><td align="center" rowspan="1" colspan="1">4938</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">-18</td></tr><tr><td align="center" rowspan="1" colspan="1">PL-5</td><td align="center" rowspan="1" colspan="1">Elemol</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0136509.g003" ref-type="fig">Fig 3J</xref></td><td align="center" rowspan="1" colspan="1">4338</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">-7</td><td align="center" rowspan="1" colspan="1">-11</td><td align="center" rowspan="1" colspan="1">-28</td></tr><tr><td align="center" rowspan="1" colspan="1">DHD-1</td><td align="center" rowspan="1" colspan="1">Berberastine-5C-Pyrimidine</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0136509.g003" ref-type="fig">Fig 3K</xref></td><td align="center" rowspan="1" colspan="1">7510</td><td align="center" rowspan="1" colspan="1">91</td><td align="center" rowspan="1" colspan="1">77</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">54</td><td align="center" rowspan="1" colspan="1">25</td></tr><tr><td align="center" rowspan="1" colspan="1">DHD-2</td><td align="center" rowspan="1" colspan="1">Berberine-5C-Pyrimidine</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0136509.g003" ref-type="fig">Fig 3L</xref></td><td align="center" rowspan="1" colspan="1">7428</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">76</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">52</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="center" rowspan="1" colspan="1">DHD-3</td><td align="center" rowspan="1" colspan="1">Berberine-4C-Pyrimidine</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0136509.g003" ref-type="fig">Fig 3M</xref></td><td align="center" rowspan="1" colspan="1">7334</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">22</td></tr><tr><td align="center" rowspan="1" colspan="1">DHD-4</td><td align="center" rowspan="1" colspan="1">Berberastine-5C- Tacrine Derivative</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0136509.g003" ref-type="fig">Fig 3N</xref></td><td align="center" rowspan="1" colspan="1">6992</td><td align="center" rowspan="1" colspan="1">77</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">17</td></tr><tr><td align="center" rowspan="1" colspan="1">DHD-5</td><td align="center" rowspan="1" colspan="1">Berberastine-3C- Tacrine Derivative</td><td align="center" rowspan="1" colspan="1"><xref rid="pone.0136509.g003" ref-type="fig">Fig 3O</xref></td><td align="center" rowspan="1" colspan="1">6726</td><td align="center" rowspan="1" colspan="1">71</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">12</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>SL, Synthetic lead; PL, Phytochemical lead; DHD, Designed heterodimer</p></fn></table-wrap-foot></table-wrap><fig id="pone.0136509.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0136509.g003</object-id><label>Fig 3</label><caption><title>Two dimentional structures of top leads used in study.</title><p>(A-E) Synthetic leads. (F-J) Phytochemical leads. (H-O) Designed heterodimers.</p></caption><graphic xlink:href="pone.0136509.g003"></graphic></fig><p>The set of medicines already in practice manifest severe side effects including nausea, vomiting, diarrhea, headache, insomnia and many other complications. Furthermore the treatment is very expensive, ranging in cost from $177 to more than $400 per month (PKR 18,000 to 40,000) [<xref rid="pone.0136509.ref034" ref-type="bibr">34</xref>]. By taking into account the side effects of chemical drugs, dietary phytochemicals were screened for a purpose to find edible plant sources as an alternate treatment of AD. The top most phytochemical showed 40% more efficient binding with receptor as compared to tacrine, however, none of them were as effective as donepezil (<xref rid="pone.0136509.t001" ref-type="table">Table 1</xref>). Berberastine, berberine, yohimbine, sanguinarine, elemol and naringenin are the worth mentioning phytochemicals in this context. The concentrations (ppm) of these phytochemicals in major source plants are given in <xref rid="pone.0136509.t002" ref-type="table">Table 2</xref>. <italic>Hydrastis canadensis</italic> (common name ‘goldenseal’), containing berberastine and berberine, is a multi-purpose homeopathic remedy [<xref rid="pone.0136509.ref038" ref-type="bibr">38</xref>]. <italic>Coptis chinensis</italic> (Chinese goldthread) is one of the 50 basic herbs used in traditional Chinese medicine and its rhizome is a source of alkaloids like berberine and others [<xref rid="pone.0136509.ref039" ref-type="bibr">39</xref>]. <italic>Berberis vulgaris</italic> (barberry), a shrub that produces edible berries rich in vitamin C, is a good source of berbrine [<xref rid="pone.0136509.ref040" ref-type="bibr">40</xref>]. Ji and Shen [<xref rid="pone.0136509.ref041" ref-type="bibr">41</xref>] reviewed anti-AChE activity of berberine to combat Alzheimer’s disease. They reported the theoretically estimated binding affinities of berberine to the enzyme AChEare very close to the experimental values. <italic>Catharanthus lanceus</italic> (known as ‘sadabahar’ in South Asia) is medicinal plant and contains 6% yohimbine in its leaves [<xref rid="pone.0136509.ref042" ref-type="bibr">42</xref>]. Mroue and coworkers showed anti-AChE activity of β-yohimbine with IC<sub>50</sub> 0.431mMin vitro [<xref rid="pone.0136509.ref043" ref-type="bibr">43</xref>]. <italic>Sanguinaria canadensis</italic> (blood root) is a historically used medicinal plant by Native Americans [<xref rid="pone.0136509.ref044" ref-type="bibr">44</xref>]. The plant contains sanguinarine and according to Houghton et al. [<xref rid="pone.0136509.ref045" ref-type="bibr">45</xref>] this phytochemical showed in vitro activity of IC<sub>50</sub> 0.23 μM against bovine erythrocyte AChE. <italic>Citrus sinensis</italic> (sweet orange) contain elemol and naringenin that also showed significant anti-hAChE activity in present study. Heo et al. [<xref rid="pone.0136509.ref046" ref-type="bibr">46</xref>] found out that when naringenin was administered at a concentration of 4.5 mg/kg body weight of mice, it significantly reduced induced forgetfulness.</p><table-wrap id="pone.0136509.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0136509.t002</object-id><label>Table 2</label><caption><title>Occurrence of the phytochemical leads in nature [<xref rid="pone.0136509.ref029" ref-type="bibr">29</xref>].</title></caption><alternatives><graphic id="pone.0136509.t002g" xlink:href="pone.0136509.t002"></graphic><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col><col align="left" valign="middle" span="1"></col></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Phytochemical</th><th align="left" rowspan="1" colspan="1">Source Plant</th><th align="center" rowspan="1" colspan="1">Concentration (ppm)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Berberastine</td><td align="left" rowspan="1" colspan="1"><italic>Hydrastis canadensis</italic></td><td align="center" rowspan="1" colspan="1">60000</td></tr><tr><td rowspan="4" align="left" colspan="1">Berberine</td><td align="left" rowspan="1" colspan="1"><italic>Coptis chinensis</italic></td><td align="center" rowspan="1" colspan="1">180000</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Coptis japonica</italic></td><td align="center" rowspan="1" colspan="1">140000</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Hydrastis canadensis</italic></td><td align="center" rowspan="1" colspan="1">120000</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>Berberis vulgaris</italic></td><td align="center" rowspan="1" colspan="1">60000</td></tr><tr><td align="left" rowspan="1" colspan="1">Yohimbine</td><td align="left" rowspan="1" colspan="1"><italic>Catharanthus lanceus</italic></td><td align="center" rowspan="1" colspan="1">100000</td></tr><tr><td align="left" rowspan="1" colspan="1">Sanguinarine</td><td align="left" rowspan="1" colspan="1"><italic>Sanguinaria canadensis</italic></td><td align="center" rowspan="1" colspan="1">120000</td></tr><tr><td align="left" rowspan="1" colspan="1">Elemol</td><td align="left" rowspan="1" colspan="1"><italic>Citrus sinensis</italic></td><td align="center" rowspan="1" colspan="1">56400</td></tr><tr><td align="left" rowspan="1" colspan="1">Naringenin</td><td align="left" rowspan="1" colspan="1"><italic>Citrus sinensis</italic></td><td align="center" rowspan="1" colspan="1">91600</td></tr></tbody></table></alternatives></table-wrap><p>One step forward, by considering the novel “multi-target-directed strategy” i.e. designing a molecule with dual or multiple binding sites [<xref rid="pone.0136509.ref047" ref-type="bibr">47</xref>], new heterodimers were planned. On the basis of structural analysis of synthetic and phytochemical leads (<xref rid="pone.0136509.t001" ref-type="table">Table 1</xref>) new heterodimers were designed as combinations of natural alkaloids berberastine and berberine with tacrine and pyrimidine rings that are active components of top synthetic leads. These heterodimers can be potential second generation AD drugs in future. As inhibitors of the human enzyme instead of torpedo they are more specific in their activity, and fulfillment of druglikeliness criteria makes them orally safer. The 2D structure of the top five newly designed drugs along with their score comparison to controls is shown in <xref rid="pone.0136509.t001" ref-type="table">Table 1</xref>. Present study demonstrates that, the designed lead berberastine-5C-pyrimidine is 91% more potent than tacrine, 25% more potent than donepezil and 10% more potent than the best synthetic database lead. Visual results for berberastine-5C-pyrimidine docking with the modeled hAChE (<xref rid="pone.0136509.g004" ref-type="fig">Fig 4A</xref>) shows that the pyrimidine ring blocks the catalytic site, five carbon chain span along the length of catalytic groove and berberastine binds to the peripheral site. <xref rid="pone.0136509.g004" ref-type="fig">Fig 4B</xref> shows O-OH type hydrogen bonding of ligand with TRP-286, TYR-124 and SER-125 residues of hAChE. The distances of hydrogen bonds were kept at < 3.50 Å cutoff.</p><fig id="pone.0136509.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0136509.g004</object-id><label>Fig 4</label><caption><title>Visual results of docking of best designed AD drug candidate, berberastine-5C-pyrimidine, into modeled hAChE.</title><p>(A) Ligand attachment conformation along the active site groove shown by solid surface ligand site. (B) Ligand attached with different residues of catalytic site, represented by sticks and colored according to the element type and element name is labeled. Active site residues are represented by sticks and enzyme by cartoons. Hydrogen bonding shown by yellow dashes and distance measured in Å.</p></caption><graphic xlink:href="pone.0136509.g004"></graphic></fig></sec></sec><sec sec-type="conclusions" id="sec012"><title>Conclusion</title><p>The present study is aimed on finding more effective hAChE inhibitors to save acetylcholine neurotransmitter that in turn can slowdown AD progression. The comparison of human and torpedo AChE enzymes at protein sequence and structure level performed in present study showed much dissimilarity that indicates that hAChE is a better drug target then tAChE. We performed docking and druglikeliness studies to elucidate the effectiveness and biological safety of synthetic molecules and dietary phytochemicals present in online chemical databases as inhibitors of hAChE. By using lead compounds of database screening we designed more highly scoring leads that gave valuable results in further lab and clinical testing to give a better relief to the AD patients against cognitive symptoms.</p></sec><sec sec-type="supplementary-material" id="sec013"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0136509.s001"><label>S1 Table</label><caption><title>Lipinski’s filer values of tested lead compounds.</title><p>(XLSX)</p></caption><media xlink:href="pone.0136509.s001.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0136509.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Cummings</surname><given-names>JL</given-names></name>, <name><surname>Cole</surname><given-names>G</given-names></name>. <article-title>Alzheimer disease</article-title>. <source>JAMA</source>. <year>2002</year>;<volume>287</volume>(<issue>18</issue>):<fpage>2335</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="pmid">11988038</pub-id></mixed-citation></ref><ref id="pone.0136509.ref002"><label>2</label><mixed-citation publication-type="other">Alzheimer's Disease International. Dementia statistics 2015. Available: <ext-link ext-link-type="uri" xlink:href="http://www.alz.co.uk/research/statistics">http://www.alz.co.uk/research/statistics</ext-link>. Accessed 2015 Jun 7.</mixed-citation></ref><ref id="pone.0136509.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Davies</surname><given-names>P</given-names></name>, <name><surname>Maloney</surname><given-names>AJ</given-names></name>. <article-title>Selective loss of central cholinergic neurons in Alzheimer's disease</article-title>. <source>Lancet</source>. <year>1976</year>;<volume>2</volume>(<issue>8000</issue>):<fpage>1403</fpage> .<pub-id pub-id-type="pmid">63862</pub-id></mixed-citation></ref><ref id="pone.0136509.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>J</given-names></name>, <name><surname>Lee</surname><given-names>HJ</given-names></name>, <name><surname>Lee</surname><given-names>KW</given-names></name>. <article-title>Naturally occurring phytochemicals for the prevention of Alzheimer's disease</article-title>. <source>J Neurochem</source>. <year>2010</year>;<volume>112</volume>(<issue>6</issue>):<fpage>1415</fpage>–<lpage>30</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1471-4159.2009.06562.x">10.1111/j.1471-4159.2009.06562.x</ext-link></comment> .<pub-id pub-id-type="pmid">20050972</pub-id></mixed-citation></ref><ref id="pone.0136509.ref005"><label>5</label><mixed-citation publication-type="book"><name><surname>Iversen</surname><given-names>L</given-names></name>. <chapter-title>Inactivation of neurotransmitters</chapter-title> In: <name><surname>Cottrell</surname><given-names>G</given-names></name>, <name><surname>Usherwood</surname><given-names>P</given-names></name>, editors. <source>Synapses</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Academic Publishers</publisher-name>; <year>1977</year> p. <fpage>137</fpage>–<lpage>53</lpage>.</mixed-citation></ref><ref id="pone.0136509.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Bartus</surname><given-names>RT</given-names></name>, <name><surname>Dean</surname><given-names>RL</given-names></name>, <name><surname>Beer</surname><given-names>B</given-names></name>, <name><surname>Lippa</surname><given-names>AS</given-names></name>. <article-title>The cholinergic hypothesis of geriatric memory dysfunction</article-title>. <source>Science</source>. <year>1982</year>;<volume>217</volume>(<issue>4558</issue>):<fpage>408</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="pmid">7046051</pub-id></mixed-citation></ref><ref id="pone.0136509.ref007"><label>7</label><mixed-citation publication-type="other">NIA. About Alzheimer's Disease: Alzheimer's Basics 2015. Available: <ext-link ext-link-type="uri" xlink:href="http://www.nia.nih.gov/alzheimers/topics/alzheimers-basics">http://www.nia.nih.gov/alzheimers/topics/alzheimers-basics</ext-link>. Accessed 2014 Jun 7.</mixed-citation></ref><ref id="pone.0136509.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Holland</surname><given-names>D</given-names></name>, <name><surname>Desikan</surname><given-names>RS</given-names></name>, <name><surname>Dale</surname><given-names>AM</given-names></name>, <name><surname>McEvoy</surname><given-names>LK</given-names></name>, <collab>Alzheimer's Disease Neuroimaging I</collab>. <article-title>Rates of decline in Alzheimer disease decrease with age</article-title>. <source>PLoS One</source>. <year>2012</year>;<volume>7</volume>(<issue>8</issue>):<fpage>e42325</fpage><comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0042325">10.1371/journal.pone.0042325</ext-link></comment> ; PubMed Central PMCID: PMC3410919.<pub-id pub-id-type="pmid">22876315</pub-id></mixed-citation></ref><ref id="pone.0136509.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Massoulié</surname><given-names>J</given-names></name>, <name><surname>Pezzementi</surname><given-names>L</given-names></name>, <name><surname>Bon</surname><given-names>S</given-names></name>, <name><surname>Krejci</surname><given-names>E</given-names></name>, <name><surname>Vallette</surname><given-names>F-M</given-names></name>. <article-title>Molecular and cellular biology of cholinesterases</article-title>. <source>Prog Neurobiol</source>. <year>1993</year>;<volume>41</volume>(<issue>1</issue>):<fpage>31</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="pmid">8321908</pub-id></mixed-citation></ref><ref id="pone.0136509.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Heinrich</surname><given-names>M</given-names></name>, <name><surname>Lee Teoh</surname><given-names>H</given-names></name>. <article-title>Galanthamine from snowdrop-the development of a modern drug against Alzheimer’s disease from local Caucasian knowledge</article-title>. <source>J Ethnopharmacol</source>. <year>2004</year>;<volume>92</volume>(<issue>2</issue>):<fpage>147</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">15137996</pub-id></mixed-citation></ref><ref id="pone.0136509.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Grutzendler</surname><given-names>J</given-names></name>, <name><surname>Morris</surname><given-names>JC</given-names></name>. <article-title>Cholinesterase inhibitors for Alzheimer’s disease</article-title>. <source>Drugs</source>. <year>2001</year>;<volume>61</volume>(<issue>1</issue>):<fpage>41</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="pmid">11217870</pub-id></mixed-citation></ref><ref id="pone.0136509.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Winblad</surname><given-names>B</given-names></name>, <name><surname>Jelic</surname><given-names>V</given-names></name>. <article-title>Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors</article-title>. <source>Alzheimer Dis Assoc Disord</source>. <year>2004</year>;<volume>18</volume>:<fpage>S2</fpage>–<lpage>S8</lpage>. <pub-id pub-id-type="pmid">15249842</pub-id></mixed-citation></ref><ref id="pone.0136509.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Kryger</surname><given-names>G</given-names></name>, <name><surname>Silman</surname><given-names>I</given-names></name>, <name><surname>Sussman</surname><given-names>JL</given-names></name>. <article-title>Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs</article-title>. <source>Structure</source>. <year>1999</year>;<volume>7</volume>(<issue>3</issue>):<fpage>297</fpage>–<lpage>307</lpage>. <pub-id pub-id-type="pmid">10368299</pub-id></mixed-citation></ref><ref id="pone.0136509.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Bartolucci</surname><given-names>C</given-names></name>, <name><surname>Perola</surname><given-names>E</given-names></name>, <name><surname>Pilger</surname><given-names>C</given-names></name>, <name><surname>Fels</surname><given-names>G</given-names></name>, <name><surname>Lamba</surname><given-names>D</given-names></name>. <article-title>Three-dimensional structure of a complex of galanthamine (Nivalin®) with acetylcholinesterase from <italic>Torpedo californica</italic>: Implications for the design of new anti-Alzheimer drugs</article-title>. <source>Proteins: Structure, Function, and Bioinformatics</source>. <year>2001</year>;<volume>42</volume>(<issue>2</issue>):<fpage>182</fpage>–<lpage>91</lpage>.</mixed-citation></ref><ref id="pone.0136509.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Greenblatt</surname><given-names>H</given-names></name>, <name><surname>Kryger</surname><given-names>G</given-names></name>, <name><surname>Lewis</surname><given-names>T</given-names></name>, <name><surname>Silman</surname><given-names>I</given-names></name>, <name><surname>Sussman</surname><given-names>J</given-names></name>. <article-title>Structure of acetylcholinesterase complexed with (−)-galanthamine at 2.3 Å resolution</article-title>. <source>FEBS Lett</source>. <year>1999</year>;<volume>463</volume>(<issue>3</issue>):<fpage>321</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="pmid">10606746</pub-id></mixed-citation></ref><ref id="pone.0136509.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Jann</surname><given-names>MW</given-names></name>. <article-title>Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease</article-title>. <source>Pharmacotherapy</source>. <year>2000</year>;<volume>20</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>12</lpage>. .<pub-id pub-id-type="pmid">10641971</pub-id></mixed-citation></ref><ref id="pone.0136509.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Schulz</surname><given-names>V</given-names></name>. <article-title>Ginkgo extract or cholinesterase inhibitors in patients with dementia: what clinical trials and guidelines fail to consider</article-title>. <source>Phytomedicine</source>. <year>2003</year>;<volume>10</volume>:<fpage>74</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="pmid">12807348</pub-id></mixed-citation></ref><ref id="pone.0136509.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Mukherjee</surname><given-names>PK</given-names></name>, <name><surname>Kumar</surname><given-names>V</given-names></name>, <name><surname>Houghton</surname><given-names>PJ</given-names></name>. <article-title>Screening of Indian medicinal plants for acetylcholinesterase inhibitory activity</article-title>. <source>Phytother Res</source>. <year>2007</year>;<volume>21</volume>(<issue>12</issue>):<fpage>1142</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="pmid">17639556</pub-id></mixed-citation></ref><ref id="pone.0136509.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Lipinski</surname><given-names>CA</given-names></name>, <name><surname>Lombardo</surname><given-names>F</given-names></name>, <name><surname>Dominy</surname><given-names>BW</given-names></name>, <name><surname>Feeney</surname><given-names>PJ</given-names></name>. <article-title>Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</article-title>. <source>Adv Drug Deliv Rev</source>. <year>2001</year>;<volume>46</volume>(<issue>1–3</issue>):<fpage>3</fpage>–<lpage>26</lpage>. .<pub-id pub-id-type="pmid">11259830</pub-id></mixed-citation></ref><ref id="pone.0136509.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Kaduszkiewicz</surname><given-names>H</given-names></name>, <name><surname>Zimmermann</surname><given-names>T</given-names></name>, <name><surname>Beck-Bornholdt</surname><given-names>H-P</given-names></name>, <name><surname>van den Bussche</surname><given-names>H</given-names></name>. <article-title>Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials</article-title>. <source>Br Med J</source>. <year>2005</year>;<volume>331</volume>(<issue>7512</issue>):<fpage>321</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">16081444</pub-id></mixed-citation></ref><ref id="pone.0136509.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Sussman</surname><given-names>JL</given-names></name>, <name><surname>Harel</surname><given-names>M</given-names></name>, <name><surname>Frolow</surname><given-names>F</given-names></name>, <name><surname>Oefner</surname><given-names>C</given-names></name>, <name><surname>Goldman</surname><given-names>A</given-names></name>, <name><surname>Toker</surname><given-names>L</given-names></name>, <etal>et al</etal><article-title>Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein</article-title>. <source>Science</source>. <year>1991</year>;<volume>253</volume>(<issue>5022</issue>):<fpage>872</fpage>–<lpage>9</lpage>. .<pub-id pub-id-type="pmid">1678899</pub-id></mixed-citation></ref><ref id="pone.0136509.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Sussman</surname><given-names>JL</given-names></name>, <name><surname>Harel</surname><given-names>M</given-names></name>, <name><surname>Frolow</surname><given-names>F</given-names></name>, <name><surname>Oefner</surname><given-names>C</given-names></name>, <name><surname>Goldman</surname><given-names>A</given-names></name>, <name><surname>Toker</surname><given-names>L</given-names></name>, <etal>et al</etal><article-title>Atomic structure of acetylcholinesterase from <italic>Torpedo californica</italic>: a prototypic acetylcholine-binding protein</article-title>. <source>Science</source>. <year>1991</year>;<volume>253</volume>(<issue>5022</issue>):<fpage>872</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="pmid">1678899</pub-id></mixed-citation></ref><ref id="pone.0136509.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Dvir</surname><given-names>H</given-names></name>, <name><surname>Jiang</surname><given-names>HL</given-names></name>, <name><surname>Wong</surname><given-names>DM</given-names></name>, <name><surname>Harel</surname><given-names>M</given-names></name>, <name><surname>Chetrit</surname><given-names>M</given-names></name>, <name><surname>He</surname><given-names>XC</given-names></name>, <etal>et al</etal><article-title>X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural evidence for an active site rearrangement</article-title>. <source>Biochemistry</source>. <year>2002</year>;<volume>41</volume>(<issue>35</issue>):<fpage>10810</fpage>–<lpage>8</lpage>. .<pub-id pub-id-type="pmid">12196020</pub-id></mixed-citation></ref><ref id="pone.0136509.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Cheung</surname><given-names>J</given-names></name>, <name><surname>Rudolph</surname><given-names>MJ</given-names></name>, <name><surname>Burshteyn</surname><given-names>F</given-names></name>, <name><surname>Cassidy</surname><given-names>MS</given-names></name>, <name><surname>Gary</surname><given-names>EN</given-names></name>, <name><surname>Love</surname><given-names>J</given-names></name>, <etal>et al</etal><article-title>Structures of human acetylcholinesterase in complex with pharmacologically important ligands</article-title>. <source>J Med Chem</source>. <year>2012</year>;<volume>55</volume>(<issue>22</issue>):<fpage>10282</fpage>–<lpage>6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1021/jm300871x">10.1021/jm300871x</ext-link></comment><pub-id pub-id-type="pmid">23035744</pub-id></mixed-citation></ref><ref id="pone.0136509.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Potestio</surname><given-names>R</given-names></name>, <name><surname>Aleksiev</surname><given-names>T</given-names></name>, <name><surname>Pontiggia</surname><given-names>F</given-names></name>, <name><surname>Cozzini</surname><given-names>S</given-names></name>, <name><surname>Micheletti</surname><given-names>C</given-names></name>. <article-title>ALADYN: a web server for aligning proteins by matching their large-scale motion</article-title>. <source>Nucleic Acids Res</source>. <year>2010</year>;<volume>38</volume>:<fpage>W41</fpage>–<lpage>W5</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/Nar/Gkq293">10.1093/Nar/Gkq293</ext-link></comment> WOS:000284148900008. <pub-id pub-id-type="pmid">20444876</pub-id></mixed-citation></ref><ref id="pone.0136509.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Kelley</surname><given-names>LA</given-names></name>, <name><surname>Sternberg</surname><given-names>MJ</given-names></name>. <article-title>Protein structure prediction on the Web: a case study using the Phyre server</article-title>. <source>Nat Protoc</source>. <year>2009</year>;<volume>4</volume>(<issue>3</issue>):<fpage>363</fpage>–<lpage>71</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nprot.2009.2">10.1038/nprot.2009.2</ext-link></comment><pub-id pub-id-type="pmid">19247286</pub-id></mixed-citation></ref><ref id="pone.0136509.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Amat-ur-Rasool</surname><given-names>H</given-names></name>, <name><surname>Saghir</surname><given-names>A</given-names></name>, <name><surname>Idrees</surname><given-names>M</given-names></name>. <article-title>Computational prediction and analysis of envelop glycoprotein epitopes of DENV-2 and DENV-3 Pakistani isolates: a first step towards Dengue vaccine development</article-title>. <source>PLoS One</source>. <year>2015</year>;<volume>10</volume>(<issue>3</issue>):<fpage>e0119854</fpage><comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0119854">10.1371/journal.pone.0119854</ext-link></comment> ; PubMed Central PMCID: PMC4361635.<pub-id pub-id-type="pmid">25775090</pub-id></mixed-citation></ref><ref id="pone.0136509.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Ye</surname><given-names>Y</given-names></name>, <name><surname>Godzik</surname><given-names>A</given-names></name>. <article-title>Flexible structure alignment by chaining aligned fragment pairs allowing twists</article-title>. <source>Bioinformatics</source>. <year>2003</year>;<volume>19</volume>(<issue>suppl 2</issue>):<fpage>ii246</fpage>–<lpage>ii55</lpage>. .<pub-id pub-id-type="pmid">14534198</pub-id></mixed-citation></ref><ref id="pone.0136509.ref029"><label>29</label><mixed-citation publication-type="other">Duke J. Dr. Duke's Phytochemical and Ethnobotanical Databases 2013. Available: <ext-link ext-link-type="uri" xlink:href="http://www.ars-grin.gov/duke/">http://www.ars-grin.gov/duke/</ext-link>.</mixed-citation></ref><ref id="pone.0136509.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Schneidman-Duhovny</surname><given-names>D</given-names></name>, <name><surname>Inbar</surname><given-names>Y</given-names></name>, <name><surname>Nussinov</surname><given-names>R</given-names></name>, <name><surname>Wolfson</surname><given-names>HJ</given-names></name>. <article-title>PatchDock and SymmDock: servers for rigid and symmetric docking</article-title>. <source>Nucleic Acids Res</source>. <year>2005</year>;<volume>33</volume>(<issue>Web Server issue</issue>):<fpage>W363</fpage>–<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gki481">10.1093/nar/gki481</ext-link></comment> ; PubMed Central PMCID: PMC1160241.<pub-id pub-id-type="pmid">15980490</pub-id></mixed-citation></ref><ref id="pone.0136509.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Mendelsohn</surname><given-names>LD</given-names></name>. <article-title>ChemDraw 8 Ultra, Windows and Macintosh Versions</article-title>. <source>J Chem Inf Comput Sci</source>. <year>2004</year>;<volume>44</volume>(<issue>6</issue>):<fpage>2225</fpage>–<lpage>6</lpage>.</mixed-citation></ref><ref id="pone.0136509.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Ashani</surname><given-names>Y</given-names></name>, <name><surname>Peggins</surname><given-names>JO</given-names><suffix>III</suffix></name>, <name><surname>Doctor</surname><given-names>BP</given-names></name>. <article-title>Mechanism of inhibition of cholinesterases by huperzine A</article-title>. <source>Biochem Biophys Res Commun</source>. <year>1992</year>;<volume>184</volume>(<issue>2</issue>):<fpage>719</fpage>–<lpage>26</lpage>. .<pub-id pub-id-type="pmid">1575745</pub-id></mixed-citation></ref><ref id="pone.0136509.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Lanctot</surname><given-names>KL</given-names></name>, <name><surname>Rajaram</surname><given-names>RD</given-names></name>, <name><surname>Herrmann</surname><given-names>N</given-names></name>. <article-title>Therapy for Alzheimer's Disease: How Effective are Current Treatments?</article-title><source>Ther Adv Neurol Disord</source>. <year>2009</year>;<volume>2</volume>(<issue>3</issue>):<fpage>163</fpage>–<lpage>80</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/1756285609102724">10.1177/1756285609102724</ext-link></comment> ; PubMed Central PMCID: PMC3002627.<pub-id pub-id-type="pmid">21179526</pub-id></mixed-citation></ref><ref id="pone.0136509.ref034"><label>34</label><mixed-citation publication-type="other">Consumer Reports. Evaluating Prescription Drugs Used to Treat: Alzheimer’s Disease. 2012.</mixed-citation></ref><ref id="pone.0136509.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Monte</surname><given-names>MM</given-names></name>, <name><surname>García Palomero</surname><given-names>E</given-names></name>, <name><surname>Valenzuela</surname><given-names>R</given-names></name>, <name><surname>Usán</surname><given-names>P</given-names></name>, <name><surname>de Austria</surname><given-names>C</given-names></name>, <name><surname>Muñoz Ruiz</surname><given-names>P</given-names></name>, <etal>et al</etal><article-title>Dual binding site acetylcholinesterase inhibitors</article-title>. <source>J Mol Neurosci</source>. <year>2006</year>;<volume>30</volume>(<issue>1</issue>):<fpage>85</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">17192640</pub-id></mixed-citation></ref><ref id="pone.0136509.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Giacobini</surname><given-names>E</given-names></name>. <article-title>Cholinesterase inhibitors for Alzheimer’s disease therapy: from tacrine to future applications</article-title>. <source>Neurochem Int</source>. <year>1998</year>;<volume>32</volume>(<issue>5</issue>):<fpage>413</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">9676739</pub-id></mixed-citation></ref><ref id="pone.0136509.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Boado</surname><given-names>RJ</given-names></name>, <name><surname>Tsukamoto</surname><given-names>H</given-names></name>, <name><surname>Pardridge</surname><given-names>WM</given-names></name>. <article-title>Drug delivery of antisense molecules to the brain for treatment of Alzheimer's disease and cerebral AIDS</article-title>. <source>J Pharm Sci</source>. <year>1998</year>;<volume>87</volume>(<issue>11</issue>):<fpage>1308</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="pmid">9811482</pub-id></mixed-citation></ref><ref id="pone.0136509.ref038"><label>38</label><mixed-citation publication-type="book"><name><surname>Hoffmann</surname><given-names>D</given-names></name>. <source>Medical herbalism: the science and practice of herbal medicine</source>: <publisher-name>Inner Traditions/Bear & Co</publisher-name>; <year>2003</year>.</mixed-citation></ref><ref id="pone.0136509.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Abascal</surname><given-names>K</given-names></name>, <name><surname>Yarnell</surname><given-names>E</given-names></name>. <article-title>Herbs and drug resistance: part 2-clinical implications of research on microbial resistance to antibiotics</article-title>. <source>Alternative & Complementary Therapies</source>. <year>2002</year>;<volume>8</volume>(<issue>5</issue>):<fpage>284</fpage>–<lpage>90</lpage>.</mixed-citation></ref><ref id="pone.0136509.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Imanshahidi</surname><given-names>M</given-names></name>, <name><surname>Hosseinzadeh</surname><given-names>H</given-names></name>. <article-title>Pharmacological and therapeutic effects of <italic>Berberis vulgaris</italic> and its active constituent, berberine</article-title>. <source>Phytother Res</source>. <year>2008</year>;<volume>22</volume>(<issue>8</issue>):<fpage>999</fpage>–<lpage>1012</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/ptr.2399">10.1002/ptr.2399</ext-link></comment><pub-id pub-id-type="pmid">18618524</pub-id></mixed-citation></ref><ref id="pone.0136509.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Ji</surname><given-names>H-F</given-names></name>, <name><surname>Shen</surname><given-names>L</given-names></name>. <article-title>Berberine: a potential multipotent natural product to combat Alzheimer’s disease</article-title>. <source>Molecules</source>. <year>2011</year>;<volume>16</volume>(<issue>8</issue>):<fpage>6732</fpage>–<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3390/molecules16086732">10.3390/molecules16086732</ext-link></comment><pub-id pub-id-type="pmid">21829148</pub-id></mixed-citation></ref><ref id="pone.0136509.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Farnsworth</surname><given-names>NR</given-names></name>, <name><surname>Blomster</surname><given-names>RN</given-names></name>, <name><surname>Buckley</surname><given-names>J</given-names></name>. <article-title>Antineoplastic and hypotensive activity of alkaloid fractions and certain alkaloids from <italic>Catharanthus lanceus</italic></article-title>. <source>J Pharm Sci</source>. <year>1967</year>;<volume>56</volume>(<issue>1</issue>):<fpage>23</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="pmid">6030488</pub-id></mixed-citation></ref><ref id="pone.0136509.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Mroue</surname><given-names>MA</given-names></name>, <name><surname>Euler</surname><given-names>KL</given-names></name>, <name><surname>Ghuman</surname><given-names>MA</given-names></name>, <name><surname>Alam</surname><given-names>M</given-names></name>. <article-title>Indole alkaloids of <italic>Haplophyton crooksii</italic></article-title>. <source>J Nat Prod</source>. <year>1996</year>;<volume>59</volume>(<issue>9</issue>):<fpage>890</fpage>–<lpage>3</lpage>.</mixed-citation></ref><ref id="pone.0136509.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Kutchan</surname><given-names>TM</given-names></name>. <article-title>Alkaloid biosynthesis-the basis for metabolic engineering of medicinal plants</article-title>. <source>The Plant Cell</source>. <year>1995</year>;<volume>7</volume>(<issue>7</issue>):<fpage>1059</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="pmid">12242397</pub-id></mixed-citation></ref><ref id="pone.0136509.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Houghton</surname><given-names>PJ</given-names></name>, <name><surname>Ren</surname><given-names>Y</given-names></name>, <name><surname>Howes</surname><given-names>M-J</given-names></name>. <article-title>Acetylcholinesterase inhibitors from plants and fungi</article-title>. <source>Nat Prod Rep</source>. <year>2006</year>;<volume>23</volume>(<issue>2</issue>):<fpage>181</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="pmid">16572227</pub-id></mixed-citation></ref><ref id="pone.0136509.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Heo</surname><given-names>HJ</given-names></name>, <name><surname>Kim</surname><given-names>M-J</given-names></name>, <name><surname>Lee</surname><given-names>J-M</given-names></name>, <name><surname>Choi</surname><given-names>SJ</given-names></name>, <name><surname>Cho</surname><given-names>H-Y</given-names></name>, <name><surname>Hong</surname><given-names>B</given-names></name>, <etal>et al</etal><article-title>Naringenin from <italic>Citrus junos</italic> has an inhibitory effect on acetylcholinesterase and a mitigating effect on amnesia</article-title>. <source>Dement Geriatr Cogn Disord</source>. <year>2004</year>;<volume>17</volume>(<issue>3</issue>):<fpage>151</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="pmid">14739537</pub-id></mixed-citation></ref><ref id="pone.0136509.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Cavalli</surname><given-names>A</given-names></name>, <name><surname>Bolognesi</surname><given-names>ML</given-names></name>, <name><surname>Minarini</surname><given-names>A</given-names></name>, <name><surname>Rosini</surname><given-names>M</given-names></name>, <name><surname>Tumiatti</surname><given-names>V</given-names></name>, <name><surname>Recanatini</surname><given-names>M</given-names></name>, <etal>et al</etal><article-title>Multi-target-directed ligands to combat neurodegenerative diseases</article-title>. <source>J Med Chem</source>. <year>2008</year>;<volume>51</volume>(<issue>3</issue>):<fpage>347</fpage>–<lpage>72</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1021/jm7009364">10.1021/jm7009364</ext-link></comment> .<pub-id pub-id-type="pmid">18181565</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Bois/explor/OrangerV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000186 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000186 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Bois
|area= OrangerV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.25. |  |